Cargando…
Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke
Autores principales: | Zeynalov, Emil, Jones, Susan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828990/ https://www.ncbi.nlm.nih.gov/pubmed/27127464 http://dx.doi.org/10.4103/1673-5374.179038 |
Ejemplares similares
-
Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice
por: Zeynalov, Emil, et al.
Publicado: (2015) -
Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice
por: Zeynalov, Emil, et al.
Publicado: (2017) -
Arginine vasopressin (AVP) expressional changes in the hypothalamic paraventricular and supraoptic nuclei of stroke-prone spontaneously hypertensive rats
por: Yi, Sun Shin, et al.
Publicado: (2012) -
Development and validation of an HPLC–MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study
por: Alrabiah, Haitham, et al.
Publicado: (2018) -
Effects of Chronic Central Arginine Vasopressin (AVP) on Maternal Behavior in Chronically Stressed Rat Dams
por: Coverdill, Alexander J., et al.
Publicado: (2012)